GlassScriptPhysician profile
Nerijus Rackauskas
NPI 1255807863
$3,221.95
in general payments reported to CMS, 2019-2025
20 companies · $737 in 2025
The $737 reported for 2025 was more than what 99% of Technician/Technologist providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $96.19 · 2023: $811 · 2024: $1,362 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,909.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $445.90 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $374.55 | 2024 | Rybrevant, Stelara, Tremfya |
| Abbvie INC. | $249.22 | 2023-2025 | |
| Ucb, INC. | $224.66 | 2024-2025 | Zilbrysq, Rystiggo |
| Immunogen, INC. | $139.25 | 2023 | Elahere |
| Beone Medicines USA, INC. | $135.74 | 2025 | Brukinsa |
| Sobi, INC | $132.35 | 2024 | |
| Rigel Pharmaceuticals, INC. | $126.83 | 2024 | Rezlidhia, Tavalisse |
| Dova Pharmaceuticals | $124.79 | 2019 | |
| Aimmune Therapeutics, INC. | $124.25 | 2024 | |
| Blueprint Medicines Corporation | $123.69 | 2024 | Ayvakit |
| Tg Therapeutics, INC. | $123.05 | 2025 | |
| Genentech USA, INC. | $120.79 | 2023 | Lunsumio |
| Jazz Pharmaceuticals INC. | $120.58 | 2024 | |
| Abbott Laboratories | $118.93 | 2023 | Freestyle Libre 3 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $118.53 | 2024 | Fruzaqla |
| Genmab U.S., INC. | $115.83 | 2025 | Epkinly |
| Eisai INC. | $106.49 | 2023 | |
| Sun Pharmaceutical Industries INC. | $100.33 | 2023 | Yonsa |
| Coherus Oncology, INC. | $96.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nerijus Rackauskas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.